Study on synergistic mechanism between the access path to national medical insurance catalogue and centralized volume-based procurement policy in China
10.3969/j.issn.1674-2982.2025.05.010
- VernacularTitle:我国医保药品目录准入路径与集中带量采购政策协同机制研究
- Author:
Meng-qing LU
1
;
Li-tian JIANG
1
;
Li-qun WU
1
Author Information
1. 深圳卫生健康发展研究和数据管理中心 广东 深圳 518028
- Publication Type:Journal Article
- Keywords:
Medical insurance;
Direct access;
Bidding access;
Negotiation access;
Centralized volume-based procurement policy;
Synergistic mechanism
- From:
Chinese Journal of Health Policy
2025;18(5):66-73
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the synergistic effect and deficiencies between the access path to national medical insurance catalogue and centralized volume-based procurement(VBP)policy,and to provide scientific references to further improve its synergistic effect.Method:The literature analysis method and policy evaluation method were adopted to explore the characteristics of the direct access,negotiated access and bidding access of medical insurance catalogue,and expound the synergistic effect and problems between different inclusion paths and the centralized VBP.Results and Conclusions:The direct access of medical insurance and the VBP policy have formed a policy loop,and have promoted the clinical application of the procured drugs.Under the negotiated access,the VBP of patented drugs is confronted with several practical problems such as the lack of evidence,incompatibility of implementation targets,conflicts in pricing mechanisms and calculation of procurement quantities.The VBP of generic drugs should be vigilant against the inhibitory effect of policy stacking on the innovation impetus.Under the bidding access,the VBP of bidding drugs should not only pay attention to the synergy effect of policies,but also focus on whether the bidding drugs meet the preconditions for centralized procurement,and the impact of the excessive price cuts on the stability of drug supply for pharmaceutical enterprises.